Lymphoma trial finds combination targeted therapy effective prior to chemotherapy

Results of a Phase II clinical trial revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).

Leave a Reply

Your email address will not be published. Required fields are marked *